Illustration of Fragment Crystallizable (Fc)-mediated cytotoxicity boosting tumor cell destruction. It highlights the increased MICA-NKG2D interaction, enhancing NK cell/T cell activation, and shows the reduction of MICA/MICB decoy release, improving NKG2D functionality. [Image courtesy of Cullinan Oncology]
Boston-based Cullinan Oncology has unveiled data for its new monoclonal antibody therapy, CLN-619, ahead of the American Society of Clinical Oncology (ASCO) 2023 meeting scheduled for June 2–6 in Chicago. The drug could potentially offer a new treatment option for patients with advanced solid tumors.Dr. Judy Wang, Associate Director of Drug Development at the Florida Cancer Specialists and Research Institute, explained the science behind the therapy. “CLN-619 is a human IgG1 monoclonal antibody that binds to cell surface ligands called MICA and MICB. These new immune therapies are trying to overcome t…